Intercept Pharma (ICPT) Gets a Hold Rating from H.C. Wainwright

By Jason Carr

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Intercept Pharma (ICPTResearch Report), with a price target of $18.00. The company’s shares closed last Friday at $17.28, close to its 52-week low of $13.88.

According to, Arce is a 4-star analyst with an average return of 14.3% and a 35.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $29.40, which is a 71.1% upside from current levels. In a report issued on July 19, Goldman Sachs also maintained a Hold rating on the stock with a $17.00 price target.

See today’s analyst top recommended stocks >>

Intercept Pharma’s market cap is currently $573M and has a P/E ratio of -2.60. The company has a Price to Book ratio of -2.87.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.